%0 Journal Article
%T Oral Isotretinoin and Its Uses in Dermatology: A Review.
%A Paichitrojjana A
%A Paichitrojjana A
%J Drug Des Devel Ther
%V 17
%N 0
%D 2023
%M 37649956
%F 4.319
%R 10.2147/DDDT.S427530
%X In 1982, the Food and Drug Administration (FDA) of the United States of America approved isotretinoin (13-cis-retinoic acid), a retinoid derivative of vitamin A, to treat severe recalcitrant acne vulgaris. Apart from its prescribed use for severe acne, evidence suggests that isotretinoin is commonly used off-label to treat mild-to-moderate acne, inflammatory skin conditions, genodermatoses, skin cancer, and other skin disorders. This is due to its anti-inflammatory, immunomodulatory, and antineoplastic properties. Some "off-label" use is successful, while others are ineffective. Therefore, this information is essential to clinicians for deciding on the appropriate use of isotretinoin. In this article, we aim to review the most updated evidence-based data about the use of oral isotretinoin in dermatology.